Borui Pharmaceuticals (688166.SH): Approval for clinical trials of tiotropium bromide inhalation powder.
The Zhichuan Finance APP reported that Borui Pharmaceutical (688166.SH) announced that its holding subsidiary, Aitmei (Suzhou) Pharmaceutical Technology Co., Ltd. (referred to as "Aitmei"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The approval allows Aitmei to conduct clinical trials for the use of its tiotropium bromide inhalation powder for chronic obstructive pulmonary disease (COPD).
Latest
3 m ago